NEW YORK, Feb 26 – Genometrix on Monday withdrew its application for an initial public offering, citing poor market conditions.

“The markets are so volatile, we decided not to proceed with it [the offering] at this time,” said Bobbie Ireland, senior manager of marketing communications at Genometrix of The Woodlands, Texas.

Ireland said the company, which filed for the IPO with the US Securities and Exchange Commission last March, has recently started working with banks in an effort to secure private financing.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.